Phase II study of pembrolizumab plus olaparib in the treatment of patients with advanced cholangiocarcinoma.

TPS4659Background: Lack of an effective second-line treatment of patients (pts) with advanced cholangiocarcinoma (CC) necessitates the development of new therapies. Preclinical studies suggest CC s...